BioCardia, Inc. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $1.6 million compared to $2.0 million in the prior year period. The company raised approximately $4.9 million in net proceeds through its At-the-Market facility and held cash reserves of $4.1 million at quarter-end. Research and development expenses decreased to $0.9 million from $1.4 million, primarily due to the close-out of the CardiAMP HF Trial. BioCardia highlighted positive regulatory interactions, noting that Japan’s PMDA supports a Shonin pre-market submission for CardiAMP Cell Therapy in Q4 2026 and the FDA indicated ongoing trials may support U.S. approval. The company operates in the biotechnology industry, developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
